Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16171323 | 0.81 | LMNA (0.42) | TLR8TLR7HRH4PRMT5LMNA | |
| SCHEMBL14666989 | 0.81 | PRMT5 (0.45) | TLR8TLR7HRH4PRMT5LMNA | |
| SCHEMBL14667018 | 0.79 | PRMT5 (0.40) | TLR8TLR7PRMT5LMNA | |
| SCHEMBL14667017 | 0.79 | PRMT5 (0.40) | TLR8TLR7HRH4PRMT5LMNA | |
| SCHEMBL14666993 | 0.77 | PRMT5 (0.38) | TLR8TLR7PRMT5LMNA | |
| SCHEMBL14670848 | 0.77 | PRMT5 (0.38) | TLR8TLR7PRMT5LMNA | |
| SCHEMBL14670847 | 0.77 | PRMT5 (0.56) | TLR8TLR7HRH4PRMT5LMNA | |
| SCHEMBL29517215 | 0.76 | DHFR (0.54) | TLR8TLR7HRH4PRMT5LMNA | |
| SCHEMBL3617192 | 0.76 | DHFR (0.54) | TLR8TLR7HRH4PRMT5LMNA | |
| SCHEMBL24621772 | 0.73 | HRH4 (0.49) | TLR8TLR7HRH4PRMT5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8969363-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | TLR8 2316/4885TLR7 2974/4885HRH4 1854/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | TLR8 2316/4885TLR7 2974/4885HRH4 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.